Adult T-cell leukemia/lymphoma is a rare and aggressive blood cancer caused by a virus that can remain silent in the body for decades before triggering disease in a small fraction of those infected.
Understanding Adult T-cell Leukemia/Lymphoma
Adult T-cell leukemia/lymphoma, commonly abbreviated as ATLL, represents a rare form of cancer that develops in certain white blood cells called T-cells, which are an essential part of the body’s immune system. This disease can appear either in the blood, where it behaves like leukemia, or in the lymph nodes and other tissues, where it acts more like lymphoma. The condition belongs to a broader category known as non-Hodgkin lymphoma, a group of cancers affecting the lymphatic system that helps defend the body against infections and diseases.[1]
What makes ATLL particularly distinctive is its connection to a specific virus. The disease develops only after infection with the human T-cell lymphotropic virus type 1, abbreviated as HTLV-1. This virus is a retrovirus, meaning it can insert its genetic material into human cells and remain there for life. However, not everyone infected with HTLV-1 will develop ATLL. In fact, only around 1 to 5 percent of people carrying the virus will eventually develop this cancer, often many decades after the initial infection.[1][2]
The disease comes in four different forms, each with distinct characteristics and severity. The acute and lymphomatous types are aggressive, fast-growing cancers that can rapidly threaten a patient’s life. In contrast, the chronic and smoldering types grow more slowly and may cause fewer symptoms initially. This variation in how the disease presents itself means that treatment approaches and expected outcomes differ significantly depending on which type a patient has.[1]
Where ATLL Occurs Around the World
Adult T-cell leukemia/lymphoma is not evenly distributed across the globe. Instead, it clusters in specific geographic regions where the HTLV-1 virus is endemic, meaning it is commonly found in the local population. The disease is most frequently diagnosed in southwestern Japan, particularly in the southern and northern islands, where it can affect as many as 27 people per 100,000 carriers each year. The Caribbean region also reports high rates of ATLL, as do parts of Central and South America, sub-Saharan Africa, and areas of the Middle East including northeast Iran and Romania.[2][6]
In contrast, ATLL remains extremely rare in North America and Europe. A recent study examining cases in North America between 2001 and 2015 found an incidence rate of only 0.06 cases per 100,000 people in the general population. In Japan, where the disease is most common, approximately 1,000 deaths occur each year from ATLL.[2]
The disease shows a slight preference for males over females, though this difference is relatively modest. ATLL typically affects older adults, with the average age at diagnosis being around 62 years. The long delay between infection with HTLV-1 and the eventual development of cancer means that most patients have carried the virus silently for many decades before symptoms appear.[2][17]
What Causes This Disease
The primary cause of adult T-cell leukemia/lymphoma is infection with the human T-cell lymphotropic virus type 1. HTLV-1 was the first retrovirus discovered in humans, and it specifically targets CD4-positive T-cells, which are white blood cells that play a crucial role in coordinating the body’s immune response. Once the virus infects these cells, it integrates its genetic material into the cell’s DNA, creating a permanent viral presence that can be passed along whenever the cell divides.[2]
The transformation from a simple viral infection to cancer involves two key viral proteins that the virus produces. The first, called transactivator protein or “tax,” plays an essential role in the initial stages of cancerous transformation. The second protein, called HTLV-1 basic leucine zipper factor or “HBZ,” is found in all infected cancer cells and drives their continued growth and multiplication. These proteins interfere with the normal controls that prevent cells from dividing uncontrollably, eventually leading to the development of leukemia or lymphoma.[2]
It is important to understand that HTLV-1 infection alone is not sufficient to cause cancer. The virus can remain dormant in the body for decades, and most infected individuals will never develop ATLL. Scientists believe that additional genetic changes must accumulate over time before the cancer emerges. Currently, doctors have no way to predict which infected patients will eventually develop ATLL and which will remain healthy carriers throughout their lives.[1]
Risk Factors for Developing ATLL
The single most important risk factor for developing adult T-cell leukemia/lymphoma is infection with HTLV-1. Without this viral infection, ATLL does not occur. The virus spreads through several routes, each presenting different levels of risk. The most common method of transmission is from mother to child, occurring through the placenta during pregnancy, at childbirth, or through breastfeeding. This mother-to-child transmission is responsible for most HTLV-1 infections worldwide.[1][12]
Sexual contact represents another significant route of transmission. The virus can pass between partners during intercourse, making it similar to other sexually transmitted infections in this regard. Blood-to-blood contact also allows the virus to spread, which can occur through sharing contaminated needles or receiving infected blood transfusions. However, screening of blood donations in many countries has greatly reduced this risk in recent decades.[1][6]
Geographic location influences risk substantially. People born or living in areas where HTLV-1 is endemic have much higher chances of exposure to the virus. This includes residents of southwestern Japan, the Caribbean islands, parts of Africa, Central and South America, and certain Middle Eastern regions. Individuals who have emigrated from these areas to other parts of the world still carry their infection and may develop ATLL years or decades later.[2]
Age also plays a role, not in acquiring the infection, but in developing the disease. Since ATLL typically emerges only after many years of viral infection, older adults face higher risk. The long latency period between infection and disease means that most patients are in their sixties when diagnosed.[17]
Recognizing the Symptoms
The symptoms of adult T-cell leukemia/lymphoma vary considerably depending on which of the four types a patient has. The aggressive forms, acute and lymphomatous ATLL, tend to produce more severe and noticeable symptoms. Patients with these types often experience swollen lymph nodes, which appear as painless lumps in the neck, underarms, or groin. The disease can also cause organs to become enlarged, particularly the liver and spleen, leading to bloating or a sensation of fullness in the abdomen.[1][5]
Many patients develop skin problems, ranging from rashes to more complex lesions. The skin involvement can be itchy and may appear as red patches or raised areas. Fatigue is another common complaint, with patients feeling exhausted even after adequate rest. This tiredness results from the disease’s effects on blood cell production and overall body function.[1]
The aggressive types frequently cause what doctors call “B symptoms,” which include unexplained fevers, drenching night sweats that soak through clothing and bedsheets, and unintentional weight loss of more than 10 percent of body weight over a six-month period. These symptoms signal that the cancer is actively growing and affecting the entire body.[5]
A particularly concerning feature of acute ATLL is elevated calcium levels in the blood, a condition called hypercalcemia. This occurs when the cancer cells release substances that cause calcium to be released from bones into the bloodstream. High calcium levels can cause confusion, extreme thirst, frequent urination, constipation, and in severe cases, life-threatening complications. Some patients also develop bone pain or fractures as the cancer affects the skeletal system.[6]
The chronic and smoldering types of ATLL typically produce milder symptoms. Patients with chronic ATLL may notice elevated numbers of white blood cells on routine blood tests, along with possible skin involvement and mild fatigue. The smoldering type lives up to its name by causing very minimal symptoms, perhaps just a few skin lesions, and may not require immediate treatment.[1][5]
Because ATLL affects the immune system, patients become more vulnerable to infections. These opportunistic infections, caused by organisms that healthy immune systems normally control, can become serious or life-threatening. Respiratory infections, fungal diseases, and other unusual infections may develop as the disease progresses.[1]
Prevention Strategies
Preventing adult T-cell leukemia/lymphoma centers on preventing HTLV-1 infection, since the virus is essential for the disease to develop. In regions where HTLV-1 is common, public health efforts focus on interrupting the main routes of transmission. The most effective intervention targets mother-to-child transmission through breastfeeding, which is the primary way the virus spreads from generation to generation.[12]
In endemic areas, pregnant women can be screened for HTLV-1 infection. When a mother tests positive, she faces a difficult decision. While breastfeeding provides numerous health benefits for infants, it also carries a significant risk of transmitting the virus. Some health authorities in highly endemic regions recommend that infected mothers avoid breastfeeding and use formula instead. This approach has proven effective in reducing new infections, though it must be balanced against the well-established benefits of breastfeeding in terms of nutrition and immune protection.[6]
Screening blood donations represents another important prevention strategy. Many countries now test donated blood for HTLV-1 antibodies and discard positive units. This practice has virtually eliminated transmission through blood transfusions in countries with robust screening programs. Unfortunately, not all nations have the resources to implement universal blood screening.[1]
Practicing safe sex can reduce the risk of sexual transmission of HTLV-1. Using condoms consistently and correctly provides protection against the virus, similar to protection against other sexually transmitted infections. Limiting the number of sexual partners and ensuring that partners are tested for HTLV-1 in endemic areas can also reduce transmission risk.[6]
For injection drug users, never sharing needles or other drug paraphernalia prevents blood-to-blood transmission of HTLV-1. Needle exchange programs and harm reduction services can help reduce this route of spread.
Unfortunately, once a person is infected with HTLV-1, no proven methods exist to prevent the progression to ATLL. The virus integrates permanently into the genetic material of infected cells, and current medical science cannot eliminate it. Researchers continue to study whether antiviral medications or immune-boosting treatments might reduce the risk of developing cancer in infected individuals, but no preventive therapy has yet been established.[2]
How the Disease Changes Normal Body Function
Understanding what happens inside the body when ATLL develops requires looking at how HTLV-1 transforms normal T-cells into cancer cells. The process begins when the virus infects CD4-positive T-cells, which are crucial coordinators of immune responses. These cells normally help the body recognize and respond to infections and other threats. Once infected, the virus inserts its genetic blueprint directly into the cell’s DNA as a single copy called a provirus.[2]
The viral proteins tax and HBZ then begin interfering with the infected cell’s normal control mechanisms. The tax protein disrupts pathways that usually prevent excessive cell division and trigger cell death when something goes wrong. This allows infected cells to multiply when they should not. The HBZ protein keeps the cancer cells growing and prevents them from dying off as they normally would. Together, these viral proteins push the infected T-cells toward becoming cancerous.[2]
As the malignant T-cells multiply, they begin to accumulate in various parts of the body. In the leukemic forms of ATLL, these abnormal cells flood the bloodstream, crowding out normal blood cells. This leads to abnormal blood counts, with very high numbers of white blood cells that do not function properly. The cancerous cells often have unusual “flower-like” nuclei with multiple lobes, which pathologists can identify under a microscope.[4]
In the lymphomatous form, the malignant cells primarily gather in lymph nodes and other lymphatic organs, causing these structures to swell. The cancer can also invade other organs including the liver, spleen, lungs, gastrointestinal tract, central nervous system, and bone marrow. This widespread involvement explains why patients experience such varied symptoms.[4]
One of the most distinctive features of ATLL is its effect on calcium balance in the body. The cancer cells produce substances including parathyroid hormone-related protein, which causes bones to release calcium into the bloodstream. This process, called osteolysis, literally means bone destruction. The bones develop holes or lesions as calcium is removed, leading to pain, fractures, and dangerously high blood calcium levels. Unlike many other cancers that affect bones, ATLL typically does not stimulate new bone formation, resulting in purely destructive bone lesions.[6]
The disease severely compromises the immune system, creating a state of immunosuppression. This happens through multiple mechanisms: the cancer cells themselves are dysfunctional immune cells that cannot perform their normal protective duties, the disease disrupts the balance of different immune cell types, and the widespread nature of the cancer overwhelms the body’s defenses. This immunosuppression makes patients highly vulnerable to infections that healthy immune systems would easily control.[2]
The cancer cells in ATLL are notably resistant to many standard chemotherapy drugs. This chemoresistance occurs because the viral proteins and accumulated genetic changes in the cancer cells activate survival pathways that help them withstand treatments designed to kill rapidly dividing cells. This resistance is one reason why aggressive forms of ATLL are so difficult to treat successfully.[2]
